Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia flag Australia · Delayed Price · Currency is AUD
8.16
+0.03 (0.37%)
Sep 17, 2026, 4:10 PM AEST

Clinuvel Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Clinuvel Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $17.45. The average 1-year stock price forecast is 113.85% higher than the current stock price, while the lowest is $9.52 (+16.67%) and the highest is $39.30 (+381.62%).

Price Target: $17.45 (+113.85%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$9.52$17.45$14.43$39.30
Change+16.67%+113.85%+76.84%+381.62%

Analyst Ratings

The average analyst rating for Clinuvel Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy777744
Buy111111
Hold000033
Sell000000
Strong Sell000000
Total888888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Jefferies
Jefferies
Buy
Maintains
$40.80$39.30
BuyMaintains$40.80$39.30+381.62%Aug 31, 2026
Morgans
Morgans
Hold
Downgrades
$10.00
HoldDowngrades$10.00+22.55%Aug 31, 2026
MA Financial Group
MA Financial Group
Buy
Maintains
$14.43
BuyMaintains$14.43+76.84%Aug 31, 2026
Bell Potter
Bell Potter
Hold
Downgrades
$11.50
HoldDowngrades$11.50+40.93%Aug 27, 2026
Canaccord Genuity
Canaccord Genuity
Hold
Downgrades
$9.52
HoldDowngrades$9.52+16.67%Aug 27, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
94.86M
from 94.02M
Increased by 0.89%
Revenue Next Year
103.03M
from 94.86M
Increased by 8.60%
EPS This Year
0.70
from 0.67
Increased by 4.51%
EPS Next Year
0.73
from 0.70
Increased by 5.18%
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingJun 30, 2022Jun 30, 2023Jun 30, 2024Jun 30, 2025Jun 30, 2026Jun 30, 2027
Revenue
65.72M78.32M88.18M95.02M94.02M94.86M
Revenue Growth
36.02%19.17%12.59%7.76%-1.05%0.89%
Gross Profit
56.47M70.80M80.45M80.20M78.21M78.74M
Gross Margin
85.92%90.40%91.23%84.41%83.18%83.00%
Operating Income
35.55M44.13M48.57M41.27M40.53M36.85M
Net Income
20.88M30.60M35.64M36.17M33.92M36.02M
EPS
----0.670.70
EPS Growth
-----6.96%4.51%
Forward PE
26.1128.3421.4913.1613.6511.69
Dividend / Share
0.040.050.050.050.050.05
Dividend Growth
60.00%25.00%---9.34%
Free Cash Flow
33.25M32.33M23.45M29.91M25.39M36.68M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.

Revenue Forecast

Revenue202720282029
High101.1M
Avg94.9M
Low89.8M

Revenue Growth

Revenue Growth202720282029
High
7.5%
Avg
0.9%
Low
-4.5%

EPS Forecast

EPS202720282029
High0.81
Avg0.70
Low0.62

EPS Growth

EPS Growth202720282029
High
21.3%
Avg
4.5%
Low
-7.5%